Acetylcysteine amide (NACA) is a novel thiol-containing antioxidant. NACA is a modified form of its parent compound N-acetylcysteine (NAC) that is a precursor of the most abundant endogenous antioxidant, glutathione (GSH). NACA demonstrated the multiple therapeutic abilities, including antioxidant, anti-apoptotic, and anti-inflammatory properties with greater efficacy compared to its parent compound. NACA treatment significantly maintained acute mitochondrial bioenergetics and normalized GSH levels following spinal cord injury. It is a new neuroprotective drug, that might be effective at slowing down nigral neuronal degeneration and illness progression in patients with Parkinson's disease.